No connection

Search Results

ALNY vs HLN

ALNY
Alnylam Pharmaceuticals, Inc.
BEARISH
Price
$313.41
Market Cap
$41.57B
Sector
Healthcare
AI Confidence
85%
HLN
Haleon plc
NEUTRAL
Price
$9.49
Market Cap
$42.18B
Sector
Healthcare
AI Confidence
80%

Valuation

P/E Ratio
ALNY
135.09
HLN
18.98
Forward P/E
ALNY
21.56
HLN
15.63
P/B Ratio
ALNY
52.57
HLN
1.9
P/S Ratio
ALNY
11.19
HLN
3.82
EV/EBITDA
ALNY
74.7
HLN
33.5

Profitability

Gross Margin
ALNY
81.64%
HLN
64.77%
Operating Margin
ALNY
12.01%
HLN
23.17%
Profit Margin
ALNY
8.45%
HLN
15.11%
ROE
ALNY
73.28%
HLN
10.27%
ROA
ALNY
6.81%
HLN
4.67%

Growth

Revenue Growth
ALNY
84.9%
HLN
0.6%
Earnings Growth
ALNY
--
HLN
92.0%

Financial Health

Debt/Equity
ALNY
3.76
HLN
0.52
Current Ratio
ALNY
2.76
HLN
0.92
Quick Ratio
ALNY
2.51
HLN
0.68

Dividends

Dividend Yield
ALNY
--
HLN
2.01%
Payout Ratio
ALNY
0.0%
HLN
37.08%

AI Verdict

ALNY BEARISH

ALNY's Piotroski F-Score of 4/9 indicates weak financial health, falling into the 'Weak' range, which raises concerns despite strong profitability and growth metrics. The company trades at a premium valuation with a P/E of 135.09 and Price/Sales of 11.19, significantly above sector averages, suggesting high growth expectations are already priced in. Insider selling activity totaling $11.62M over six months signals bearish sentiment from within the company, particularly from senior officers. While revenue growth is impressive at 84.9% YoY and ROE is exceptionally high at 73.28%, the lack of earnings consistency and negative free cash flow (implied by missing data) undermine sustainability. The Graham Number of $17.64 and intrinsic value of $16.24 are far below the current price of $313.41, indicating severe overvaluation unless future growth materializes at extraordinary rates.

Strengths
Exceptionally high ROE of 73.28%, indicating efficient use of equity capital
Strong gross margin of 81.64% reflecting pricing power and cost control
Impressive 84.9% YoY revenue growth, signaling robust market demand
Risks
Piotroski F-Score of 4/9 indicates weak financial health, with potential red flags in profitability consistency and cash flow
Debt/Equity ratio of 3.76 is high for a biotech firm, suggesting elevated financial leverage
Insider selling of $11.62M in six months, particularly from CEO and CFO, signals internal skepticism
HLN NEUTRAL

Haleon plc presents a stable fundamental profile with a Piotroski F-Score of 6/9 and a current price of $9.49 that sits comfortably between its Graham Number ($7.49) and Intrinsic Value ($14.75). While the company exhibits strong profitability margins and a healthy debt-to-equity ratio of 0.52, it is hampered by stagnant revenue growth (0.60%) and a completely bearish technical trend (0/100). The massive spike in earnings growth (92%) appears decoupled from top-line performance, suggesting efficiency gains rather than market expansion. Overall, the stock is a value-play with limited immediate momentum.

Strengths
Strong gross margins at 64.77% and operating margins at 23.17%
Conservative leverage with a Debt/Equity ratio of 0.52
Stable financial health indicated by a Piotroski F-Score of 6/9
Risks
Near-zero revenue growth (0.60% YoY) indicating market saturation or lack of pricing power
Severe bearish technical momentum (Technical Trend: 0/100)
Liquidity concerns with a Quick Ratio of 0.68 and Current Ratio of 0.92

Compare Another Pair

ALNY vs HLN: Head-to-Head Comparison

This page compares Alnylam Pharmaceuticals, Inc. (ALNY) and Haleon plc (HLN) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI Chat
Markets
Profile